AQST (Aquestive Therapeutics) LT-Debt-to-Total-Asset : 0.37 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aquestive Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.37.

Aquestive Therapeutics's long-term debt to total assets ratio declined from Dec. 2023 (0.57) to Dec. 2024 (0.37). It may suggest that Aquestive Therapeutics is progressively becoming less dependent on debt to grow their business.

Aquestive Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aquestive Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aquestive Therapeutics LT-Debt-to-Total-Asset Chart

Aquestive Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.59

0.86

0.68

0.57

0.37

Aquestive Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.57	0.26	0.30	0.33	0.37

Aquestive Therapeutics LT-Debt-to-Total-Asset Calculation

Aquestive Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	37.468	/	101.424
	=	0.37

Aquestive Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	37.468	/	101.424
	=	0.37

Aquestive Therapeutics (NAS:AQST) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aquestive Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aquestive Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Technology Drive, Warren, NJ, USA, 07059

Website

https://www.aquestive.com

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Executives

Cassie Jung	officer: SVP, Operations	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel	director, officer: Chief Innovation/Tech Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Carl N Kraus	officer: Chief Medical Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki	officer: SVP, Research & Development	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt	officer: Chief Medical Officer	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris	director	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd	officer: SVP-Operations/Value Delivery	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender	officer: SVP, General Counsel	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber	officer: SVP-Chief Strategy/Dev Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr	officer: Interim CFO
John T. Maxwell	officer: SVP-Chief Financial Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall	director, officer: President and CEO	30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta	director	C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154